$VTVT News

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program Transcript

BTIG Reiterates Buy on vTv Therapeutics, Maintains $57 Price Target

vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026

vTv Therapeutics stock jumps on FDA orphan drug status

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease

vTv Therapeutics Receives FDA's Orphan Drug Designation For HPPD To Treat Sickle Cell Disease

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)

vTv Therapeutics Completes Enrollment In Its Phase 3 Cadisegliatin As Adjunctive Therapy In Type 1 Diabetes Trial

vTv Therapeutics to Participate in September Investor Conferences

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HC Wainwright & Co. Maintains Buy on vTv Therapeutics, Lowers Price Target to $42

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

vTv Therapeutics Q2 EPS $(1.05) Misses $(0.99) Estimate

BTIG Maintains Buy on vTv Therapeutics, Raises Price Target to $57

cAMPfield lands $180M to build gut disease drug

vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next

vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable

vTv Therapeutics Inc. (NASDAQ:VTVT) Reports Massive Q1 Earnings Beat, But Stock Dips on "Sell the News" Reaction